India’s largest pharma company Sun Pharmaceuticals is seeing a technical break-out, after its June quarter results. June quarter sales were down 10 percent mainly on account of a decline in the US business, which accounted for 29 percent of sales. … [Read more...] about Ideas For Profit | Will Sun Pharma’s steady India business, US speciality portfolio help it do well in FY22?
At the front, the X50 Pro sports a 6.56-inch FHD+ OLED curved panel with a 90Hz refresh rate and a tiny punch-hole cutout for the 32MP front camera. Under the hood, there is a Snapdragon 765G chipset with an integrated 5G modem. Vivo X50 Pro also packs a 4,315 mAh battery with 33W fast charging. … [Read more...] about Vivo X50 series launch in India on July 16 – here’s everything you need to know
IndusInd Bank reported steady operating performance during Q1FY21. NII for the quarter grew by 16% YoY/2% QoQ to Rs 3,309 cr, despite a lower loan growth of 2% YoY/-4% QoQ. NII growth was mainly driven by NIM improvement of 3bps QoQ/23bps YoY at 4.28%. Operating profit of the bank increased by 10% YoY/1% QoQ to Rs 2,861 cr. Lower operating profit growth was mainly due to 9% YoY/14% QoQ fall in other income. Provision remained higher at Rs 2,259 cr, which includes additional Covid provision of Rs 920 cr (Total Covid provision at 1,203 cr). Profit for the quarter fell by 68% YoY to Rs 461 cr, primarily, due to higher provisioning. On a sequential basis, PAT grew by 53%. On the business front, the bank has witnessed de-growth in advances at 4.2% on QoQ basis while on YoY basis it grew by 2.4%. Bank has gained strong traction in deposit growth at 5% QoQ vs. 7% QoQ fall in Q4FY20. Liquidity coverage ratio of the bank improved to 124% vs. 112% QoQ. … [Read more...] about Hold IndusInd Bank; target of Rs 557: Arihant Capital